OS Therapies reports 'positive' results from Phase 2b trial of OST-HER2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 30 2025
0mins
Clinical Trial Results: OS Therapies reported positive outcomes from its Phase 2b trial of OST-HER2, showing a 35% event-free survival rate at one year for treated patients, compared to 20% in historical controls.
Safety Profile: The treatment demonstrated a favorable safety profile, with severe adverse events primarily being grade 3 and no patients discontinuing the study due to these events, highlighting its potential as a quality-of-life improvement for patients with lung metastatic osteosarcoma.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSTX
Wall Street analysts forecast OSTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OSTX is 11.50 USD with a low forecast of 6.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.380
Low
6.00
Averages
11.50
High
17.00
Current: 1.380
Low
6.00
Averages
11.50
High
17.00
About OSTX
OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
OS Therapies (OSTX) Reports Positive OST-HER2 Data but Shares Drop 4.52%
- Clinical Trial Progress: OS Therapies' Phase 2b trial of OST-HER2 revealed that immune blood biomarkers in the interferon gamma pathway effectively distinguish long-term from short-term survivors, bolstering their Biologics License Application (BLA) submission.
- Regulatory Approval Path: The company plans to submit its BLA to the FDA by Q2 2026, with regulatory approvals anticipated in the UK, US, and Europe by the end of 2026, indicating strong potential for market entry.
- Poor Stock Performance: Despite positive clinical data, OSTX shares fell 4.52% to $1.48, trading 2.5% below the 20-day and 12.8% below the 50-day simple moving averages, reflecting market caution regarding future performance.
- Mixed Market Signals: The current RSI of 47.78 suggests neutral territory, while the MACD indicates a potential bullish signal, reflecting complex market sentiment towards OSTX, necessitating investor vigilance.
Continue Reading
Oncolytics Biotech Appoints New Executives to Accelerate Cancer Treatment Progress
- Market Potential: The global immuno-oncology market is projected to surge from $35 billion to $185.69 billion, reflecting strong demand for coordinated immune system activation, attracting capital influx and driving the precision medicine market to $537.17 billion.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will enhance the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks, with a median duration of response reaching 17 months, indicating potential for accelerated approval in a setting with no FDA-approved options.
- FDA Design Approval: Oncolytics secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its leadership in the oncology immunotherapy space.
Continue Reading